Exelixis, Inc. (EXEL)
68.98
-0.86
(-1.23%)
USD |
NASDAQ |
Nov 13, 16:00
68.98
0.00 (0.00%)
After-Hours: 19:50
Exelixis Price to Book Value : 9.204 for Nov. 13, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 9.318 |
| November 11, 2026 | 9.433 |
| November 10, 2026 | 9.417 |
| November 09, 2026 | 9.572 |
| November 06, 2026 | 9.282 |
| November 05, 2026 | 9.168 |
| November 04, 2026 | 9.707 |
| November 03, 2026 | 9.648 |
| November 02, 2026 | 9.357 |
| October 30, 2026 | 9.258 |
| October 29, 2026 | 8.833 |
| October 28, 2026 | 8.843 |
| October 27, 2026 | 8.719 |
| October 26, 2026 | 8.687 |
| October 23, 2026 | 8.610 |
| October 22, 2026 | 8.714 |
| October 21, 2026 | 8.616 |
| October 20, 2026 | 8.591 |
| October 19, 2026 | 8.363 |
| October 16, 2026 | 8.303 |
| October 15, 2026 | 8.383 |
| October 14, 2026 | 8.138 |
| October 13, 2026 | 7.940 |
| October 12, 2026 | 7.981 |
| October 09, 2026 | 7.987 |
| Date | Value |
|---|---|
| October 08, 2026 | 7.875 |
| October 07, 2026 | 7.797 |
| October 06, 2026 | 7.783 |
| October 05, 2026 | 7.852 |
| October 02, 2026 | 7.791 |
| October 01, 2026 | 7.731 |
| September 30, 2026 | 7.793 |
| September 29, 2026 | 7.917 |
| September 28, 2026 | 7.879 |
| September 25, 2026 | 7.851 |
| September 24, 2026 | 7.822 |
| September 23, 2026 | 7.658 |
| September 22, 2026 | 7.850 |
| September 21, 2026 | 7.724 |
| September 18, 2026 | 7.878 |
| September 17, 2026 | 7.895 |
| September 16, 2026 | 7.665 |
| September 15, 2026 | 7.681 |
| September 14, 2026 | 7.588 |
| September 11, 2026 | 7.576 |
| September 10, 2026 | 7.752 |
| September 09, 2026 | 7.874 |
| September 08, 2026 | 7.785 |
| September 04, 2026 | 7.966 |
| September 03, 2026 | 7.982 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| BioMarin Pharmaceutical, Inc. | 1.772 |
| Alnylam Pharmaceuticals, Inc. | 6.130 |
| Cytokinetics, Inc. | -- |
| Gilead Sciences, Inc. | 16.00 |
| Ionis Pharmaceuticals, Inc. | 12.28 |
Price to Book Value Related Metrics
| PE Ratio | 20.64 |
| PS Ratio | 7.315 |
| PEG Ratio | 0.5075 |
| Price to Free Cash Flow | 15.73 |
| Price | 68.98 |
| Earnings Yield | 4.84% |
| Market Cap | 16.88B |
| PEGY Ratio | 0.5075 |
| Operating PE Ratio | 18.19 |
| Normalized PE Ratio | 20.63 |